<DOC>
	<DOC>NCT00430352</DOC>
	<brief_summary>This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma. All patients will receive MabThera 375mg/m2 body surface area, as an intravenous infusion, every 8 weeks. The anticipated time on study treatment is 1-2 years, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; histologically confirmed grade 1, 2 or 3a follicular nonHodgkin's lymphoma; patients who have received adequate (&gt;=8 cycles) induction therapy with MabThera as first line treatment, or treatment for relapsed disease; demonstrated partial or complete response to induction therapy. stable or progressive disease after most recent induction therapy; transformation to high grade lymphoma; patients with prior or concomitant malignancies, except nonmelanoma skin cancer or adequately treated in situ cancer of the cervix.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>